Main image Main image

Cend Therapeutics in the News

November 8, 2017

Since May 2017, about 20 publications – from almost as many academic groups – have used and independently validated the DrugCendR iRGD tumor penetrating technology. These papers have corroborated our mechanistic understanding on the tumor-specific drug transport (CendR) pathway activated by iRGD peptide, and also further validated its therapeutic efficacy in a variety of tumor models. The complete list is available here.

 

 

 

Number of publications using the DrugCendR iRGD technology

October 23, 2017

DrugCendR Inc. is presenting its well-validated technology for the treatment of solid tumors at the San Diego Innovation Showcase on Thursday, October 26th, 2017. More information on the event website sandiegoinnovationcouncil.org/showcase.

October 9, 2017

DrugCendR Inc. will participate in the BIO Investor Forum in a session on Wednesday, October 18th, 2017 at 10:30 am PST. The conference takes place on October 17th and 18th Westin St. Francis Hotel, San Francisco. More information on the event website https://www.bio.org/events/bio-investor-forum.

For more information.





RECENT NEWS & RESOURCES

APR 7

INNOVATION Kyoto 2016 LPs Completes Strategic Investment in DrugCendR Inc.

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.


“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”


Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.

ARCHIVES